Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 15, 2014 - Issue 10
Submit an article Journal homepage
541
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluations

Efficacy of ruxolitinib for myelofibrosis

Fabio PS SantosHospital Israelita Albert Einstein, Hematology and Oncology Center, São Paulo, SP, Brazil
&
Srdan VerstovsekThe University of Texas M. D. Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Unit 0428, Houston, TX 77030, USA+1 713 745 3429; +1 713 745 0930; [email protected]
Pages 1465-1473 | Published online: 24 May 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hakan Parlakpinar & Mehmet Gunata. (2021) Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacology and Immunotoxicology 43:6, pages 651-665.
Read now

Articles from other publishers (6)

Tanja Fetter, Paul Smith, Tugce Guel, Christine Braegelmann, Thomas Bieber & Joerg Wenzel. (2020) Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Frontiers in Immunology 11.
Crossref
Joerg Wenzel. (2019) Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nature Reviews Rheumatology 15:9, pages 519-532.
Crossref
Joyce O’Shaughnessy, Angela DeMichele, Cynthia X. Ma, Paul Richards, Denise A. Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang & Hope S. Rugo. (2018) A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment 170:3, pages 547-557.
Crossref
Paolo Strati, Lucia Masarova, Prithviraj Bose, Naval Daver, Naveen Pemmaraju & Srdan Verstovsek. (2017) Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leukemia Research 57, pages 85-88.
Crossref
A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian, R Mesa, F Passamonti, V Ribrag, G Schiller, A M Vannucchi, D Zhou, D Reiser, J Zhong & R P Gale. (2016) A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 31:4, pages 896-902.
Crossref
Uddalak Bharadwaj, Moses M. Kasembeli & David J. Tweardy. 2016. STAT Inhibitors in Cancer. STAT Inhibitors in Cancer 95 161 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.